Immucell, Inc. (ICCC)

[BioSpecialist]

CORONAVIRUS GEM ..underpriced low float stock

[ClayTrader]

* * $ICCC Video Chart 01-21-2020 * *

Link to Video - click here to watch the technical chart video

[Marvy]

Vaccine?

[$Pistol Pete$]

$ICCC Daily and Weekly Charts

[$Pistol Pete$]

$ICCC Daily Chart

[stocktrademan]

$ICCC recent news/filings

bullish 7.40
gap up on earnings
hidden bullish divergence
continuation
above average green volume

## source: finance.yahoo.com

Thu, 12 Nov 2015 21:08:39 GMT ~ IMMUCELL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition


read full: http://biz.yahoo.com/e/151112/iccc8-k.html
*********************************************************

Thu, 12 Nov 2015 21:05:00 GMT ~ ImmuCell Announces Results for Third Quarter of 2015

[Marketwired] - ImmuCell Corporation , a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced ...

read full: http://finance.yahoo.com/news/immucell-announces-results-third-quarter-210500368.html
*********************************************************

Thu, 12 Nov 2015 12:07:03 GMT ~ Q3 2015 ImmuCell Corp Earnings Release - After Market Close


read full: http://biz.yahoo.com/research/earncal/20151112.html?t=iccc
*********************************************************

Tue, 10 Nov 2015 20:46:10 GMT ~ 11-5-2015 “ImmuCell to Announce Third Quarter 2015 Financial Results”

[at noodls] - 6bc0b971-bbb6-44b0-aade-21db8c59004f.pdf ImmuCell FOR IMMEDIATE RELEASE: ImmuCell to Announce Third Quarter 2015 Financial Results Conference Call Scheduled for Thursday, November 12, 2015 at 4:30 PM EST ...

read full: http://www.noodls.com/view/4EEDC0DA5D37CA5423DA253B28034D61598E38C5
*********************************************************

Thu, 05 Nov 2015 13:00:00 GMT ~ ImmuCell to Announce Third Quarter 2015 Financial Results

[Marketwired] - ImmuCell Corporation , a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, will report third ...

read full: http://finance.yahoo.com/news/immucell-announce-third-quarter-2015-130000704.html
*********************************************************

$ICCC charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$ICCC company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ICCC/company-info
Ticker: $ICCC
OTC Market Place: Not Available
CIK code: 0000811641
Company name: ImmuCell Corp.
Incorporated In: DE, USA


$ICCC share structure

## source: otcmarkets.com

Market Value: $22,607,252 a/o Nov 13, 2015
Shares Outstanding: 3,055,034 a/o Aug 10, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.1

$ICCC extra dd links

Company name: ImmuCell Corp.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ICCC+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ICCC+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ICCC+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ICCC/news - http://finance.yahoo.com/q/h?s=ICCC+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ICCC/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ICCC/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ICCC+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ICCC
DTCC (dtcc.com): http://search2.dtcc.com/?q=ImmuCell+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=ImmuCell+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=ImmuCell+Corp.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ICCC
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000811641&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ICCC/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ICCC/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ICCC&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ICCC
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ICCC/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ICCC+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ICCC+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ICCC
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ICCC
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ICCC+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ICCC/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ICCC+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ICCC.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ICCC
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ICCC/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ICCC/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ICCC
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ICCC
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ICCC:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ICCC
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ICCC



$ICCC DD Notes ~ http://www.ddnotesmaker.com/ICCC

[Roy London]

ICCC continues on low volume

[Roy London]

ICCC strong low volume move...weekly in line to go!!

[DragonKrys]

Big Q1 coming. From the recently filed 10-K:

This positive trend has continued into the first quarter of 2015, and this new level of sales demand for First Defense® has exceeded our production capacity and available inventory. We project that sales (shipped to customers) of First Defense® during the first quarter of 2015 will be approximately 62% over the first quarter of 2014. Based upon orders received as of March 18, 2015 that we expect to be in excess of our finished goods inventory available to ship during the balance of the first quarter of 2015, we estimate that we will have a backlog of orders for First Defense® aggregating at least $795,000 as of March 31, 2015. This estimate of the backlog as of March 31, 2015 will be further increased by orders received after March 18, 2015. The 62% projected increase in sales of First Defense® during the first quarter of 2015 over the first quarter of 2014 would be increased further to approximately 105% if we could ship the $795,000 in orders discussed above before April 1, 2015. We are making the investments necessary to increase our production capacity to meet the growing sales demand for First Defense®.

[Smarter_Investing]

Is The Next Biotech Boom For Cows? Why Immucell Corporation Is The Easiest Double In The Stock Market

http://stks.co/e1hKk

[TREND1]

ICCC D

[TREND1]

ICCC D

[TREND1]

ICCC D

[Drmicrocap]

ImmuCell Announces Increase in Product Sales and Other Annual Financial Results

.

Marketwired
ImmuCell Corporation
February 13, 2014 8:00 AM















.


.





..
.
.
PORTLAND, ME--(Marketwired - Feb 13, 2014) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and twelve-month periods ended December 31, 2013.

During the three-month period ended December 31, 2013, product sales increased by 9.7%, or $138,000, to $1,559,000 in comparison to $1,421,000 during the same period in 2012. During the twelve-month period ended December 31, 2013, product sales increased by 11.5%, or $617,000, to $6,007,000 in comparison to $5,390,000 during the same period in 2012.

"We have now increased product sales during the last six consecutive quarters and for twelve of the last thirteen quarters. Sales of First Defense® and related product line extensions increased by 16.5% during the fourth quarter and 14.4% during the year ended December 31, 2013," commented Michael F. Brigham, President and CEO.

The net operating (loss) was ($210,000) during the three-month period ended December 31, 2013, in contrast to a net operating income of $12,000 during the same period in 2012. The net (loss) was ($151,000), or ($0.05) per share, during the three-month period ended December 31, 2013, in comparison to a net (loss) of ($17,000), or ($0.01) per share, during the same period in 2012.

Net operating (loss) was ($20,000) during the twelve-month period ended December 31, 2013, in contrast to net operating income of $245,000 during the same period in 2012. Net income was $117,000, or $0.04 per share, during the twelve-month period ended December 31, 2013, in comparison to net income of $90,000, or $0.03 per share, during the same period in 2012.

Regarding the fourth quarter loss, Mr. Brigham added, "During the fourth quarter, we incurred approximately $110,000 in expenses as we initiated our planned investment in a Nisin production plant for Mast Out®. Further, we reduced production output during the last six months of 2013 in order to replace and repair certain pieces of critical process equipment, which resulted in an increase in cost of goods sold. We expect our gross margin percentage to be more in line with our historical norms during 2014."

Cash, cash equivalents and short-term investments increased by 7%, or $342,000, to $5,255,000 as of December 31, 2013, in comparison to $4,914,000 as of December 31, 2012. Stockholders' equity increased by 2%, or $201,000, to $9,396,000 as of December 31, 2013, in comparison to $9,195,000 as of December 31, 2012. The Company had 3,026,000 shares of common stock outstanding as of December 31, 2013.



(Unaudited)
For the Three-Month Periods Ended December 31, For the Twelve-Month Periods Ended December 31,
(In thousands, except per share amounts) 2013 2012 2013 2012

Product sales $ 1,559 $ 1,421 $ 6,007 $ 5,390
Costs of goods sold 951 671 2,947 2,336
Gross margin 608 750 3,060 3,054

Product development expenses 325 234 1,154 918
Selling and administrative expenses 493 503 1,926 1,891
Operating expenses 818 737 3,080 2,809

NET OPERATING (LOSS) INCOME (210 ) 13 (20 ) 245

Other (expenses) revenues, net (43 ) (24 ) 225 (53 )

(LOSS) INCOME BEFORE INCOME TAXES (253 ) (11 ) 205 192

Income tax (benefit) expense (102 ) 6 88 102

NET (LOSS) INCOME $ (151 ) $ (17 ) $ 117 $ 90

Weighted average common shares outstanding:
Basic 3,021 3,019 3,019 3,018
Diluted 3,021 3,019 3,085 3,108
NET (LOSS) INCOME PER SHARE:
Basic $ (0.05 ) $ (0.01 ) $ 0.04 $ 0.03
Diluted $ (0.05 ) $ (0.01 ) $ 0.04 $ 0.03


(In thousands) As of December 31, 2013 As of December 31, 2012
Cash, cash equivalents and short-term investments $ 5,255 $ 4,914
Total assets 10,961 11,030
Net working capital 6,632 6,697
Stockholders' equity $ 9,396 $ 9,195



About ImmuCell: ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, (http://www.immucell.com).




Contact:


Michael F. Brigham
President and CEO
[phone] Ext. 3106

[JD400]

Insider Buying

ICCC ROTHSCHILD JONATHAN E Director Aug 23 Buy 3.98 1,500 5,965 465,280

[Drmicrocap]

ImmuCell Announces Increase in Product Sales and Continued Profitability
MarketwiredPress Release: ImmuCell Corporation – Tue, May 14, PORTLAND, ME--(Marketwired - May 14, 2013) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month period ended March 31, 2013.

During the three-month period ended March 31, 2013, product sales increased by 8%, or $130,000, to $1,847,000 in comparison to $1,717,000 during the same period in 2012.

Net operating income was $327,000 during the three-month period ended March 31, 2013, in comparison to net operating income of $281,000 during the same period in 2012. The net income was $204,000, or $0.07 per share, during the three-month period ended March 31, 2013, in comparison to net income of $155,000, or $0.05 per share, during the same period in 2012. The improved financial performance is largely due to increased gross margin from sales of First Defense®.

"In this extremely challenging dairy and beef economy with a record low milk-to-feed price ratio narrowing our customers' profit margins, our product sales increased by 8% and 5% during the three-month and twelve-month periods ended March 31, 2013, respectively," commented Michael F. Brigham, President and CEO. "This sales growth contributed to our continued profitability, while we are actively seeking a partner to help us complete the development and commercialization of Mast Out®."

Cash, cash equivalents and short-term investments increased by 8%, or $392,000, to $5,305,000 as of March 31, 2013, in comparison to $4,914,000 as of December 31, 2012. Stockholders' equity increased by 2%, or $219,000, to $9,413,000 as of March 31, 2013, in comparison to $9,195,000 as of December 31, 2012. The Company had 3,019,000 shares of common stock outstanding as of March 31, 2013.

About ImmuCell:
ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, (http://www.immucell.com).

Contact:
Michael F. Brigham, President and Chief Executive Officer
[phone] Ext. 3106




(Unaudited)
For the Three-Month Periods Ended March 31,
(In thousands, except per share amounts) 2013 2012

Product sales $ 1,847 $ 1,717
Costs of goods sold 793 704
Gross margin 1,054 1,013

Product development expenses 267 248
Sales, marketing and administrative expenses 461 484
Other operating expenses 728 732

NET OPERATING INCOME 326 281

Other revenues (expenses), net 44 (10 )

INCOME BEFORE INCOME TAXES 370 271

Income tax expense 166 116

NET INCOME $ 204 $ 155

Weighted average common shares outstanding:
Basic 3,019 3,016
Diluted 3,084 3,103
NET INCOME PER SHARE:
Basic $ 0.07 $ 0.05
Diluted $ 0.07 $ 0.05




(Unaudited)
As of
March 31, 2013 As of
December 31, 2012
(In thousands)
Cash, cash equivalents and short-term investments $ 5,305 $ 4,914
Total assets 11,111 11,030
Net working capital 7,082 6,697
Stockholders' equity $ 9,413 $ 9,195


.
.
Contact:.
.

Michael F. Brigham
President and Chief Executive Officer
[phone] Ext. 3106

[DragonBits]

Still waiting after all these years.

[DragonBits]

flybucks, I would expect between a double and a triple from current prices on partnsership news. Depends on what details would be released.

But as to when news about a partnership might happen, I have no way to be able to predict that.

[flybucks]

bounced from around $3 to around $9 with Pfizer agreement...

can we get another triple from here or near here?

[flybucks]

enjoy your commentary on both ymb and ihub

have an opinion on date of next catalyst?

marketing agreement/co-op...then approval?

manufacturer still at the ready even though negative news recently?

[DragonBits]

I am the same bits as YM. There is no news on ICCC. The only thing I can deduce from the price action is that if there is partneship news, the stock is likely to mova ggressively up, somewhere north of 10.e very fast up.

I can't guess how close partenrship news is, there are approval steps regarding mast-out that can be predicted as regards to timing, such as Effectiveness complete step. But overall approval timing can't be predicted.

[flybucks]

are u bits_since_1980 on ymb?

looks like modest accumulation going on last couple of days

how close do you suppose for any announcements on partnering or approval of Mast-Out?

i presume that is what SP appreciation is awaiting?

[DragonBits]

Test, does anyone follow this stock on IHUB?

[Penny Roger$]

~ $ICCC ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $ICCC ~ Earnings expected on Monday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=ICCC&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=ICCC&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/ICCC?
~ OTC Markets: http://www.otcmarkets.com/stock/ICCC/company-info
~ Google Finance: http://www.google.com/finance?q=ICCC
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=ICCC#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=ICCC+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=ICCC
Finviz: http://finviz.com/quote.ashx?t=ICCC
~ BusyStock: http://busystock.com/i.php?s=ICCC&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=ICCC&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=ICCC
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=ICCC
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=ICCC
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=ICCC
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=ICCC
~ MarketWatch: http://www.marketwatch.com/investing/stock/ICCC/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=ICCC
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=ICCC
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=ICCC&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=ICCC&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=ICCC&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[DragonBits]

Pfizer Won’t Break Up Animal Unit as Lilly Shows Interest in Some Products

QBy Tom Randall and Bob Langreth - Jul 21, 2011 12:24 PM CT .

Pfizer Inc. (PFE), the world’s biggest drugmaker, said it has no plans to break up the company’s animal health unit after Eli Lilly & Co. (LLY) expressed interest in buying some of its products.

Lilly, which had $1.39 billion in sales from animal-health products last year, is monitoring Pfizer’s plans to divest its unit and will pursue assets deemed of interest, Chief Financial Officer Derica Rice said today in a conference call. Pfizer wants a sale or spinoff of the unit and doesn’t foresee breaking it up, said Joan Campion, a company spokeswoman.

Pfizer Chief Executive Officer Ian Read said on July 7 he is divesting the company’s animal health and nutrition units to buy back shares and focus on developing new drugs. The units may fetch $22 billion, according to Seamus Fernandez, an analyst at Leerink Swann & Co. Pfizer’s animal health unit had sales last year of $3.48 billion.

“While we are evaluating a variety of options including a sale, spinoff or other transaction, we believe we will favor one overall option rather than dividing assets and business operations,” Campion said today in an e-mail.

Pfizer’s review of its options for the unit will take 12 to 24 months, Campion said. The company doesn’t plan further announcements about the unit until 2012, she said.

Pfizer shares rose 27 cents, or 1.4 percent, to $20.17 at 1:22 p.m. in New York Stock Exchange composite trading. Lilly rose $1.23, or 3.2 percent, to $39.40, for the biggest intraday gain since May 3.

Evolving Situation
“We will watch how that situation evolves, and if there are some assets that become available that we are interested in, yes, we will pursue them,” Lilly’s Rice said in a conference call with analysts. “It is very early to speculate” what type of transaction Pfizer is seeking, he said.

Lilly isn’t likely to buy the unit outright, Fernandez said in an e-mail. In order to maintain its quarterly dividend of 49 cents a share, which Rice has said Lilly will do, the company would have to issue more stock and risk diluting earnings or use so much cash that it would hurt the company’s credit ratings, Fernandez said. The deal is also unlikely to be approved by antitrust regulators, he said.

“I simply don’t think they are interested, and a $12 billion-plus deal would be a pretty big deal,” Fernandez wrote. If another buyer emerges and faces regulatory hurdles, Lilly might be able to purchase some assets from the acquiring company, he said.

Lilly is interested in expanding its Elanco animal heath unit’s offerings in vaccines and pet products, as well as boosting its presence in Europe, Jeff Simmons, president of the division, said in a June 29 telephone interview. Elanco’s biggest product line is feed additives for cattle and poultry.

“We are going to be opportunistic in animal health,” Simmons said. “We are looking for additional assets. We are not interested in acquiring for the sake of acquiring; it has got to have a strategic element.”
To contact the reporters on this story: Tom Randall in New York at [e-mail]; Robert Langreth in New York at [e-mail]

[DragonBits]

Merck manual for mastitis.


http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/110903.htm

[DragonBits]

Sell Stocks, Buy Cows: Casey

Feeling lost in your quest for fresh money-making opportunities these days? Well, you're not alone. Even a globe-trotting speculator like Doug Casey, who's namesake firm, Casey Research, prides itself on being "Intensely Curious, Focused on Facts" says there's just aren't many good places to hide anymore.

"Good investment ideas are not thick underfoot these days" says Casey, adding that "the next few years will be marvelous from the point of view of a speculator, but horrible for the average guy." Casey's definition of a speculator is not a gambler or a trader, but rather someone who capitalizes on politically caused distortions in the marketplace, and he's expecting a lot of them. As such, and not surprisingly, Casey loves gold and hates the dollar.

On the former, Casey sees the bull market in gold eventually entering a "mania stage" which he thinks could push it to $5000 an ounce. Even so, he says the recent run-up to $1500 is cause for "hesitation," yet still broadly advises that people "should own a lot of gold."

As for the dollar, and major currencies in general, his commentary is more caustic, as he blasts the long-term washout that looms as a result of "trillions of currency units that all these stupid governments are creating."

Casey openly does not like to link his predictions with time lines. He says in the years to come, the dollar will trade to its intrinsic value (as in -- be worth the paper it's printed on), which "will be quite ugly." This despite his belief that "the EU is going to fall apart and euro will cease to exist" within the next 5 to 10 years.

And there's more sunshine where that came from.

Casey says "your biggest single risk is political. You must diversify so all your money isn't in the control of one government." He says he's heavily diversified outside of the U.S., and "bought a lot of agricultural land in Argentina." True to his word, Casey now spends most of his time living and investing in South America.

So if you already own gold and you're not moving to South America, what else looks good?

"I am a big believer in cattle. I recommend building herds, both dairy and beef" because he says it's probably the cheapest major market he can think of. Interestingly, he has no interest in trading cattle (futures).

And if you're not quite ready to embrace farming, he has one other suggestion: "I would be short bonds. You can make a killing doing that."

So there you have it. Just when you thought your pessimism could not be eclipsed, Doug Casey comes forth and sets a new benchmark for bearishness.


http://finance.yahoo.com/blogs/breakout/sell-stocks-buy-cows-casey-152817594.html?sec=topStories&pos=7&asset=&ccode=

[DragonBits]

A little difficult to trade this stock at current prices, hard to pick a high enough price to ensure that you can buy back the same number of shares at a lower price. Most people are holding on.

[DragonBits]

Pfizer deal caused the stock to spike to about 9.67, I would expect a new partnership to be a better deal and spike the stock to above 10.00.

[DragonBits]

Possible partnership terms.

Sell 200,000 shares at 10.00 to the parnter, have them fund the FDA test batches, do a split of the profits.

This establishes a higher value for ICCC, makes it possible they could be in play to be taken over, either that or the partner could sell their shares at a big profit if ICCC gets approved and sales ramp up.

The last partnership boosted the stock to something like 9.65, so I am thinking a new partnership should take the stock to above 10.00.

[DragonBits]

surf, you must still own a position in ICCC ?

BTW, after following some of your posts for a time, congrats on being a good investor.

[surf1944]

ImmuCell Comments on Status of Zero Milk Discard Claim for Mast Out(R)

Press Release Source: ImmuCell Corporation On Thursday June 9, 2011, 8:00 am EDT

PORTLAND, ME--(Marketwire - 06/09/11) - ImmuCell Corporation (NASDAQ:ICCC - News) today announced that the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA) has accepted the pivotal Nisin residue data in milk and has assigned a zero milk discard time and zero meat withdrawal period. These 'claims' are subject to obtaining the Human Food Safety (HFS) Technical Section Complete Letter and ultimately approval of the New Animal Drug Application (NADA).

Mast Out® is an intramammary treatment for subclinical mastitis in lactating dairy cattle. The remaining element of the HFS Technical Section is the submission to and acceptance by the FDA of ImmuCell's Nisin residue method in milk to measure Nisin concentrations around the newly assigned tolerance limit.

'Zero Discard' means that there would be no requirement to discard milk during treatment or for a period of time thereafter. ImmuCell management believes that this would be a significant competitive advantage differentiating Mast Out® from all other intramammary antibiotics. Market acceptance of this novel product, as a tool capable of revolutionizing the way that mastitis is treated, is critically dependent upon achieving this zero milk discard claim.

"The ruling -- second in importance only to effectiveness -- provides renewed impetus to achieve approval as quickly as possible," commented Dr. Joseph H. Crabb, Vice President and Chief Scientific Officer.

Currently, the FDA is taking a closer look at antibiotic residues in all food products, while global markets are demanding milk products with lower somatic cell counts, indicative of infection status. This market environment may be favorable to the launch of a product like Mast Out®.

About ImmuCell:
ImmuCell Corporation's (NASDAQ:ICCC - News) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, (http://www.immucell.com).

[DragonBits]

My 2 year target, assuming MastOut is approved, is between 20-100.

Depends on their future partner, and the market at the time, what sort of PE are assigned to stocks.

[DragonBits]

Likely close to 5.00 this month, but I suspect it won't break it, but it should exceed it's 52 week high.

Just my guess.

[DragonBits]

On July 15, 2010, ImmuCell Corporation (the Company) entered into a Development and Manufacturing Agreement with Lonza Sales Ltd. of Basel, Switzerland. This contract covers terms under which the Company will pay Lonza to exclusively i) develop the Company’s proprietary manufacturing process at commercial scale and ii) manufacture the Nisin Active Pharmaceutical Ingredient for use in its product Mast Out ® , which is subject to approval by the U.S. Food and Drug Administration before any sales can be made. Financial obligations of the Company to Lonza are staged on a commitment by commitment basis, as the intended development process is conducted.

Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

[Norm2]

Mastitis is an infection, caused by several types of bacteria. Cows carry bacteria around with them in their nasal cavity. Infectiion can be shared by contact or by flies. SinoFresh destroys the bacteria.
This is what i believe. Well worth the cost.

Norman

[DragonBits]

Mastitis Control Programs:
Bovine Mastitis and Milking Management

What is interesting is that for every clinical case of mastitis, there will be 15 to 40 sub-clinical cases. This is the market ICCC is targeting with Mast Out.


Clinical Mastitis -- visible signs of mastitis which include:

Mild signs flakes or clots in the milk, may have slight swelling of infected quarter.
Severe signs secretion abnormal, hot, swollen quarter or udder; cow may have a fever, rapid pulse, loss of appetite, dehydration and depression; death may occur.
Subclinical Mastitis -- no visible signs of the disease:

Somatic cell count (SCC) of the milk will be elevated.
Bacteriological culturing of milk will detect bacteria in the milk.
Causes the greatest financial loss to dairy farmers through lowered milk production.
For every clinical case of mastitis, there will be 15 to 40 sub-clinical cases.
Somatic Cell Count (SCC) -- the number of leukocytes or white blood cells per milliliter of milk.

Normal milk will have less than 200,000 cells per milliliter.
An elevated SCC is an indication of inflammation in the udder.
Bulk tank SCC gives an indication of the level of sub-clinical mastitis and the loss of milk production in a herd due to mastitis.

http://www.ag.ndsu.edu/pubs/ansci/dairy/as1129w.htm

[DragonBits]

Norm, mastitis is an infection of the mammary glands in cows. I believe the infection enters by one of the teats. Treatment is centered on the mammary glands.

SinoFresh™ Nasal Mist combines the soothing, moisturizing benefits of a saline rinse with effective cleansing ingredients to target and remove nasal-sinus irritants. The germ-fighting formula removes airborne irritants like bacteria, dust, and pollen while it freshens and invigorates your nose and sinuses.

The sinuses and mammary glands aren't related.

Good luck in getting a dairy farmer to use SinoFresh to spray their cows nose.

[Norm2]

I have my own idea about mastitis

I agree with the concept that increasing the money income from milk is the key concept and the optimum way is to improve the revenue from cows with sub-clinical mastitis. A vaccine is not a good idea, because it would increase the number of antibodies in the cow, and will lower the value of the milk if given to "healthy" cows.

My idea of treatment can be done with very low cost. Some onr can buy from Walgreens or online a couple of bottles of SinoFresh for about $15 each.
Pick a grouping of about 100 cows whose milk output can be can be separated from the rest of the herd so its value can be determined and its value measured.

I would run this test about 3 months My concept is that the group of cows
would have their noses sprayed twice a week for about three months. Ideally, the group would be compared with a "control" grup of a simulat nomber of cows that did not get the spray

This is certainly not a "clinical trial" No FDA involvement at all. I think it is quite legal. The farme will have an idea of how much additional income he can get by using the procedure.

I think it will be far about the cost of producing the few ounces of drug used in the process


Norman

[DragonBits]

New mastitis treatment may offer alternative to

The important part of this for me was the current market for antibiotics for mastis. I have seen this 40-50 million number before. Of course the market ICCC is going for is sub-clinical mastis, which is potentially larger and has no treatment for.

New mastitis treatment may offer alternative to antibiotics
Agricultural Research, Feb, 2006 by Jan Suszkiw

A new weapon could be on tap for fighting bacteria that cause mastitis, an inflammatory udder disease of dairy cows costing around $2 billion annually in animal and milk-production losses.

In trials at ARS's Bovine Functional Genomics Laboratory, Beltsville, Maryland, scientists Max Paape and Douglas Bannerman showed that injecting the cows' mammary glands with the sugar Poly-x reduced mastitis infections at about one-twelfth the cost of antibiotics.

The sugar, a type known as a "polysaccharide," occurs naturally in the cell walls of certain yeasts. But when administered to nonlactating ("dry") dairy cows, the polysaccharide serves as a kind of biochemical bugle call that mobilizes the animals' immune system, especially to produce bacteria-killing 1 white blood cells.

"Previous work at Beltsville indicated that increasing the cell count in milk will prevent infection," says Paape, a dairy scientist. "Poly-x increases the cell count in dry-cow secretions for the first 5 days of the dry period, thus preventing infection by bacteria."

Today's mastitis-control programs often use several measures, like diagnostic testing, sanitation, herd separation, animal culling, teat dips, and antibiotic treatment. For conventional dairy operations, antibiotics use can be expensive, costing about $10 a cow, or $45 million nationwide, Paape estimates. The practice is also controversial, with concerns focusing on the potential for environmental contamination and the emergence of antibiotic-resistant bacteria.

Paape and Bannerman see some advantages to using Poly-x as a natural alternative--the lack of residues being one. Another is the expense. A tube of antibiotic costs around $2.50. By comparison, the ingredient cost for an experimental Poly-x treatment is only 20 cents.

http://findarticles.com/p/articles/mi_m3741/is_2_54/ai_n16069030/

[Norm2]

royg

You are a person with the qualifications I hoped to reach.

I have no experience with dairy management I have experience with SinoFresh and think it s a great product. Close to being a "miracle drug"

Here is a link which gives a little information on the problem I think it will address.

http://www.ag.ndsu.edu/pubs/ansci/dairy/as1129w.htm



Norman

[DragonBits]

Roy, I have no real dog in this discussion either. Norm just posed a question about a nasal spray of which I know nothing about and has nothing to do with ICCC. I don't even know if the nasal spray has anything to do with mastis.

I only asked what I thought were logical questions.

ICCC has a teat wipe that they sell on a regular basis.

[royg1927]

John,

I haven't been following this coversation so my comment(s) may be less than useless.

That said, as a previous owner/operator of a significant sized dairy, a couple of statements raise questions from my experience.

Spray - easy to apply?? What frequency would be required? Maybe so with feed bunk lock-ups. But I don't want to add a single labor intensive factor unless there is clear indication of a production margin gain of some multiple of the projected cost.

Improve the quantity and quality of milk produced? What milk market prices milk on quality, say SSC count? There is usually a butterfat component, yes, but what favorable effect if any would such treatment provide?

I seriously (very seriously) doubt notions such as systemic low grade infections being related to clinical mastitis. What pathogens by name? Subject to what antibiotic sensitivity tests?
Flies introducing infections through a drop of leaking milk on the teat end (as a significant source of infection?). Seemingly reasonable speculation perhaps, but where is the evidence? The statistically significant double blind trials?

On the positive hand, if (-IF-) it is clear that any device/product/procedure would with certainty result in a significant and sustainable increase in production with low cost of application, such item would result in a stampede for adoption by the commercial dairy industry.

We (the commercial dairymen) are financially astute, practical and hard headed. Whatever "The Thing" is will be shunned pie-in-the-sky if clear advantage is not demonstrable for me and my neighbors down the road.

Not trying to provoke an argument. I have no dog in this fight.

[DragonBits]

norm, how do you or I make any money from this?

[Norm2]

john
I would expect that the herd owner makes money because his cows produce more and better quality milk than the same group of cows would untreated. They will have less infections than untreated cows. You could say that they are more contented, like the ones Carnation used to talk about.

A very significant increase in product, for a rather small increase in cost.

Norman

[DragonBits]

Norm, so what disease does this spray prevent? How do you make money from this?

[Norm2]

John
I don't have a bottle of SinoFresh at hand to check its content list. You can find it by searching for SinoFresh on the internet. I believe its advantage is that it is a topical spray, and very little if any gets into the animal's blood supply, much different from the case with hormones used to increase milk production

I think it will produce a large decrease in the bacteria content of the mucus on the cow's nose.

When cows are in pastures, they are visited by flies. Flies land on the nose and go also to teats which are leaking milk. The teats are very soft and subject to minute scratches from weeds or plants. allowing bacteria from the flies feet to get into the blood. So cows with infections can spread it to other cows.

So all cows in the herd should be treated periodically. I don't think that there will be a measurable change in the chemical content of the cows milk. There will be a significant increase in the volume production of milk, as well as better quality. More money for the herd owner. Only a slight cost of treatment.

Norman

[DragonBits]

Norm, I don't know. Medicating cattle is introducing drugs into the food supply. The fact that it is over the counter may mean it is easier to get approved, but for something to be effective it often has negative effects if consumed on a regular basis or in too large of amounts. So the FDA is pretty careful about that subject.

Nisin is already approved as a food preservative, so I think approval is more likely. Nisin is the active ingredient in MastOut.

What is the active ingredient in the spray?

[Norm2]

I am wondering if it would be illegal to spray the noses of dairy cattle with an over-counter medication?

I don't think it would be very expensive. I would expect such cows to produce more milk with less cell content. than unsprayed cows..

Norman

[DragonBits]

Norm, it is expensive and time consuming to get FDA approval for anything that would prevent Mastitis in cows and qualify for elimination of the throw away program that the FDA mandates for cows treated with antibiotics.

So the nasal spray would have to be a mircle drug to get someone to pay for testing it.

I think ICCC has been working on this for 10 years. It isn;t a huge money maker for someone like pfizer but it could be 100 million on sales which would be a big deal for someone as small at ICCC. The big deal would be to eliminate the milk throwaway.